Business WireNovember 4, 2026
HepQuant to Present Five Abstracts at AASLD’s The Liver Meeting® 2026
HepQuant announced the presentation of five abstracts at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, November 5–9 in Denver. The studies highlight the clinical application of the HepQuant DuO® test and its Disease Severity Index (DSI) result.
Business WireJune 23, 2026
FDA Approves the HepQuant SHUNT® Liver Diagnostic Test to Quantify Risk of Large Esophageal Varices in Adult Patients with Compensated Cirrhosis (Child Pugh Class A)
The FDA has granted premarket approval (PMA) for the HepQuant SHUNT® Liver Diagnostic Test to aid in identifying patients unlikely to require EGD.
PRNewswire-PRWeb June 8, 2026
HepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory Excellence
PRESS RELEASE HepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory Excellence Denver, CO – June 8, 2026 – HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announced that its laboratory has achieved accreditation from the College of American Pathologists (CAP), recognizing…
PRNewswire-PRWeb | May 27, 2026
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO®
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO® PRNewswire-PRWeb DENVER, Colo., May 27, 2026 — HepQuant, LLC announced the presentation of three studies at the 2026 Congress of the European Association for the Study of the Liver (EASL), showcasing the clinical and research value…
In The News
Journal of Clinical Medicine
HepQuant DuO Study Named a Journal of Clinical Medicine Editor’s Choice Article
We are pleased to announce that the paper, “Utilization of the Disease Severity Index (DSI) from the HepQuant DuO Test Enhances Clinical Decision Making in Compensated Advanced Chronic Liver Disease,” has been selected as a Journal of Clinical Medicine Editor’s Choice Article for the third quarter of 2026.
June 15, 2026